Ronald Matricaria has been appointed to the board of directors of Invitrogen, the company announced last week. He replaces William Mercer, who is retiring. Matricaria was formerly the chairman and CEO of St. Jude Medical, where he increased revenues from $225 million to more than $1 billion. Prior to that, he worked for Eli Lilly, serving as CEO of Lilly subsidiary Cardiac Pacemakers and as executive vice president of the pharmaceutical division of Eli Lilly, in addition to other roles.
Werner Schafer joined the supervisory board of BioVision July 1. Schafer replaced Erich Mayer. Schafer is the chairman of the Brahms biotechnology company in Berlin, and has many years of experience in the pharmaceutical and diagnostic industry. BioVision specializes in the identification of disease-relevant peptides and proteins using its Peptidomics technologies.
Augustine Yee was appointed as vice president of business development for Archemix. Yee comes to Archemix from Prometheus Laboratories, where he was vice president and head of business and corporate development. He holds a BS in molecular biology from the University of California at San Diego and a JD from Pepperdine University School of Law.
Robert Brown has been named vice president of corporate development for Serologicals. Most recently, Brown was senior vice president of corporate development at Andrx. Brown holds a BS in chemistry from Neumann College.
Daniel Von Hoff has been appointed to the scientific advisory board of Halozyme Therapeutics. Von Hoff is currently a professor of medicine, pathology and molecular and cellular biology at Arizona Health Sciences Center. He is also head of the Translational Genomics Research.